166 related articles for article (PubMed ID: 37568663)
1. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
Dannehl D; Engler T; Volmer LL; Tegeler CM; Fusshoeller J; Gabrysch E; Eissler K; Seller A; Grischke EM; Hahn M; Gruber I; Schochter F; Pfister K; Veselinovic K; Leinert E; Rack B; Fink V; Janni W; Brucker SY; Hartkopf AD; Schäffler H
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568663
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S; Jin Q; Vincuilla J; Buehler R; Ryan S; Stokes S; Parker T; Mittendorf EA; King TA; Weiss A; Partridge AH; Bychkovsky BL; Curigliano G; Tayob N; Lin NU; Garber JE; Tolaney SM; Lynce F
NPJ Breast Cancer; 2024 Apr; 10(1):28. PubMed ID: 38627457
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Morganti S; Bychkovsky BL; Poorvu PD; Garrido-Castro AC; Weiss A; Block CC; Partridge AH; Curigliano G; Tung NM; Lin NU; Garber JE; Tolaney SM; Lynce F
Oncologist; 2023 Jul; 28(7):565-574. PubMed ID: 37210568
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
[TBL] [Abstract][Full Text] [Related]
5. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
[TBL] [Abstract][Full Text] [Related]
6. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmaña J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im SA; Jager A; Jóhannsson ÓÞ; Lakhani SR; Janni W; Linderholm B; Liu TW; Loman N; Korde L; Loibl S; Lucas PC; Marmé F; Martinez de Dueñas E; McConnell R; Phillips KA; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Španić T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ;
Ann Oncol; 2022 Dec; 33(12):1250-1268. PubMed ID: 36228963
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Yamauchi H; Toi M; Takayama S; Nakamura S; Takano T; Cui K; Campbell C; De Vos L; Geyer C; Tutt A
Breast Cancer; 2023 Jul; 30(4):596-605. PubMed ID: 37005966
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
Schäffler H; Mergel F; Pfister K; Lukac S; Fink A; Veselinovic K; Rack B; Fink V; Leinert E; Dimpfl M; Englisch A; Tegeler CM; Seller A; Grischke EM; Hahn M; Volmer LL; Engler T; Frevert ML; Taran FA; Janni W; Brucker SY; Hartkopf AD; Dannehl D
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003555
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry.
Frevert ML; Dannehl D; Jansen L; Hermann S; Schäffler H; Huwer S; Janni W; Juhasz-Böss I; Hartkopf AD; Taran FA
Arch Gynecol Obstet; 2024 Jun; 309(6):2811-2819. PubMed ID: 38472501
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
13. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
14. Association between basal-like phenotype and
Jung J; Kang E; Gwak JM; Seo AN; Park SY; Lee AS; Baek H; Chae S; Kim EK; Kim SW
Curr Oncol; 2016 Oct; 23(5):298-303. PubMed ID: 27803593
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
[TBL] [Abstract][Full Text] [Related]
17. Awareness and Availability of Routine Germline
Lux MP; Decker T; Runkel ED; Niyazov A; Quek RGW; Marschner N; Harbeck N
Breast Care (Basel); 2022 Feb; 17(1):40-46. PubMed ID: 35350106
[TBL] [Abstract][Full Text] [Related]
18. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
19. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
